Purdue Pharma
DopesickPurdue Pharma was the marketing arm that promoted OxyContin, a prescription opioid whose commercial success and assurances of safety helped reshape medical practice even as its misuse spread. The company’s story in the book moves from family-owned pharmaceutical business to aggressive national promotion, federal prosecution, and a long aftermath in which a criminal settlement proved only one measure of the damage attributed to the drug and the broader normalization of opioids.
Origins and the OxyContin business
OxyContin was approved by the U.S. Food and Drug Administration in late 1995. Its developer, Purdue Frederick, was a little-known family-owned company based in Stamford, Connecticut. The Sackler family acquired it in 1952 from its original Manhattan owners. At the time, the company had only a few employees and annual sales of $20,000. The three brothers who bought it—Mortimer Sackler, Raymond Sackler, and Arthur Sackler—had trained as research psychiatrists. Their early business grew around over-the-counter products, including laxatives, earwax remover, and Betadine, an antiseptic also used to wash down the Apollo 11 spacecraft after its historic mission.
The company expanded internationally in the 1970s, acquiring Scottish and British drug companies and entering pain relief. When OxyContin reached the market, Purdue Frederick’s marketing arm, Purdue Pharma, managed its promotion and sales. The division had been launched in Delaware, a state known as a corporate tax haven. The distinction between developer and marketer matters in the book’s account: Purdue Frederick supplied the corporate entity later prosecuted, while Purdue Pharma carried the sales campaign into doctors’ offices and the wider medical world.
Promotion and assurances of safety
Purdue Pharma made the drug’s controlled-release delivery system central to its safety claims. David Haddox, a pain specialist who became the company’s principal public advocate for OxyContin, told audiences that addiction risk was extremely low when the medicine was taken as prescribed. A company training session for doctors in 1996 likewise characterized doctor-caused addiction as exceptionally rare. These assurances helped frame addiction as an unusual outcome rather than a foreseeable risk of expanding opioid use.
The sales campaign was backed by growing financial incentives and direct outreach. Sales-representative bonuses rose from $1 million in 1996, the year OxyContin entered the market, to $40 million in 2001. New patients could receive starter coupons for free prescriptions, each redeemable for a thirty-day supply. Purdue also held more than forty national pain-management and speaker-training conferences during the drug’s first five years. The events brought doctors, nurses, and pharmacists to resorts from Boca Raton, Florida, to Scottsdale, Arizona; travel and expenses were paid, and attendees received items such as beach hats bearing the OxyContin logo. More than five thousand health professionals attended.
The company’s influence extended beyond its own representatives. The book describes a wider landscape in which pain organizations promoted expanded opioid use for long-term chronic pain while receiving millions of dollars from drug manufacturers. Reporting on those financial relationships helped prompt a 2012 Senate investigation targeting the American Pain Foundation and Purdue, among other organizations and pharmaceutical companies. The account thus places Purdue’s campaign within a professional climate shaped not only by sales calls but also by the funding and authority surrounding pain advocacy.
Abuse evidence and the federal case
Purdue claimed that it did not know of OxyContin’s abuse problems until February 2000. Yet Curtis Wright had signed off on a review of the drug application filed in 1995 that described risks associated with crushing the tablets. The review noted that crushing could release the drug immediately instead of gradually, that withdrawal symptoms had occurred in some clinical-trial participants, and that 68 percent of the oxycodone in a crushed pill could be recovered after it was liquefied and injected. The contrast between this information and the company’s public assurances became central to questions about what Purdue knew and when.
The legal case was built from a growing documentary record. Files from Arnold Fayne McCauley’s case—including sales-representative notes and depositions—were folded into material gathered by Gregg Wood and John Brownlee’s team. Brownlee’s office was secretly logging millions of records in spreadsheets. The Wood Reports appeared four or five times a week, and one employee was assigned solely to catalog documents. Together, the records strengthened Brownlee’s belief that Purdue had knowingly concealed OxyContin’s addictiveness.
The proposed resolution faced sustained pressure. An observer connected to the case said the agreement had been weakened as it passed through United States Department of Justice headquarters, while Purdue representatives, including Rudy Giuliani, lobbied against felony indictments of executives. The financial negotiations also shifted sharply: Purdue initially offered $10 million, while the government’s initial proposal was $1 billion. In October 2006, the night before the plea deadline was due to expire, a senior Justice Department officer called Brownlee at home at a Purdue lawyer’s request and urged him to extend the deadline. Brownlee refused to give the negotiations more time.
In May 2007, Brownlee announced the settlement in a downtown Roanoke office building. Purdue pleaded guilty to felony misbranding, admitting that for six years it had fraudulently marketed OxyContin as less prone to abuse and less likely to produce narcotic side effects than immediate-release versions. The company and its top executives, Paul Goldenheim, Michael Friedman, and Howard Udell, were also subject to criminal and civil resolutions. The company paid a reported $634.5 million in fines; the detailed directives included money forfeited to the United States, payments resolving government and private civil claims, and funds for Virginia fraud investigations and its prescription-monitoring program. The executives pleaded guilty to misdemeanor versions of the crime, with $34.5 million in executive fines paid by the firm on their behalf.
Community consequences and the limits of the settlement
The consequences documented in the book reach beyond the courtroom. In distressed rural towns and hollows, Purdue’s representatives could target injured people who were out of work or receiving disability benefits and had Medicaid coverage. OxyContin was not confined to rural areas, but the book describes its distinctive visibility in these places, where vulnerability and ready access to medical prescriptions intersected. By 2012, local prevention workers still reported that they had not understood the connection between prescription pills and heroin until later; earlier medication take-back efforts had not singled out opioids.
In Roanoke, heroin had long been treated as an inner-city drug and largely handled as a matter for police and court reporters. The highly publicized skin-popping incident involving local weathermen briefly served as a wake-up call, but journalists, including the book’s narrator, treated it as an anomaly. The incident received more local attention than Purdue’s federal settlement the following year. This misjudgment reflects a larger narrative pattern: the company’s role in expanding opioid exposure could remain less visible than the sensational incidents and street-level consequences that followed.
Art Van Zee had warned Purdue that Lee County might be a sentinel area, comparing its significance to early HIV outbreaks in San Francisco and New York. He did not then know that the OxyContin crisis would develop into a heroin epidemic, followed by further deaths involving HIV and hepatitis C. The sequence links the company’s prescription-drug campaign to later harms without reducing those harms to a single cause. In another example of how responsibility could be deflected, Ronnie Jones portrayed himself as a wholesaler removed from the final act of drug use and argued that he supplied heroin cheaply and more safely than Baltimore. The book compares that self-exculpating account with Purdue’s own assurances about its product, showing how claims of distance from the consequences could recur at different points in the supply chain.
Reformulation, litigation, and continuing dispute
The federal settlement did not end the legal or public argument over Purdue’s role. Eight years after the 2007 sentencing, lawsuits against Purdue and other opioid makers and distributors were being filed by communities and governments across the country, including Everett, Washington; the state of Ohio; Cabell County, West Virginia; and Dickenson County, Virginia. West Virginia and Kentucky had already obtained settlements of $10 million and $24 million, respectively. The book presents these payments as modest victories in a growing effort to make pharmaceutical companies answer for the public costs imposed on communities.
The original OxyContin was eventually withdrawn after Purdue introduced a reformulated version designed to deter abuse. Two weeks before Jesse Bolstridge’s death, the U.S. Food and Drug Administration informed Barbara Van Rooyan that part of her petition had been approved: the request to withdraw approval of the original formulation. By then, Purdue had already withdrawn it voluntarily, three years after the reformulation reached the market. Van Rooyan believed her petition might have helped push the change, but later concluded that the loss of the original product’s patent was likely a more important reason than either her appeal or a new belief that the reformulation was safer.
Andrew Kolodny argued that the deepest harm was not limited to the misbranding charge: Purdue had made the medical community more comfortable with opioids as a class, while proper FDA oversight might have prevented the epidemic. That assessment places the company’s significance at the level of institutional practice as well as product marketing. The book closes its account of Purdue against the continuing human and financial contrasts of the crisis: Ronnie Jones growing gray in prison, Kristi Fernandez preparing seasonal decorations for Jesse’s grave, and the Sackler family falling from sixteenth to nineteenth place on the Forbes list of America’s richest families. The settlement recorded a crime and imposed penalties; it did not settle the larger question of how corporate promotion, medical authority, regulation, and community vulnerability combined to produce lasting consequences.
